Shaping the future of migraine targeting Calcitonin-Gene- Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs)

DOI: https://doi.org/10.1186/s10194-019-1009-9

[Section 1] The journey then had several stages, and the caravan was always enriched with new data, up to the current stage we celebrate today, a new pharmacological target dedi- cated to migraine and based on monoclonal antibodies directed against either CGRP or the CGRP receptor or on small molecules with antagonism activity towards the CGRP [35, 187].

We must consider that the clinical application of these drugs directed to the CGRP, members of the first and only pharmacological classes created de novo for migraine treatment, acting on the CGRP biomarker of disease [188], maintain their long-term efficacy reverting this way the migraine disease to a quasi-silent state [189].

With these premises, we can define this CGRP new pharmacological class as Disease-Modifying-Migraine- Drugs (DMMDs), for the benefit of the huge number of patients needing therapies that, if promptly used, can slow down or freeze or revert the natural course of migraine [190].

Acknowledgement A machine generated summary based on the work of Martelletti, Paolo; Edvinsson, Lars; Ashina, Messoud. 2019 in The Journal of Headache and Pain.

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies